NeXT Personal molecular residual disease (MRD) assay was featured in five presentations and posters at ASCO. Key highlights include:
Join this webinar to:
Dr. Haudenschild joined Personalis in 2012 to build the company's professional services department. Previously, he was an Associate Director at Illumina Inc., leading commercial sequencing. At Lynx Therapeutics and Solexa, he developed massively parallel protocols for studying small RNA and DNA. Dr. Haudenschild received his Ph.D. in Molecular and Cellular Enzymology from the University Louis Pasteur in 1995 and completed postdoctoral research at Washington State University and the University of California at Berkeley.
Dr. Chen joined Personalis in 2011 as Chief Scientific Officer and was promoted to Senior Vice President R&D and Chief Medical Officer in 2021. A physician scientist, Dr. Chen has extensive expertise in systems biology, translational genomics, knowledge engineering, and scientific product development. He co-founded and served on the board of several companies, including Ingenuity Systems. Dr. Chen has also served on the clinical faculty at Stanford University School of Medicine. He received a BS in Computer Science, an MD, and an MS in biomedical informatics from Stanford. He completed his Chief Residency and Dermatology Specialty Training at Stanford and is board certified.
Christelle Johnson, PhD, is an Associate Director and Field Applications Scientist at Personalis, Inc., with over 9 years of experience in cancer genomics and immuno-oncology. She holds a PhD in Tumor Immunobiology from the University of Louisville School of Medicine and a Master's in Microbiology and Immunology from the American University of Beirut. Christelle has held postdoctoral research positions at Harvard Medical School and Cornell University. Her expertise spans research, clinical applications, and business, making her a well-rounded professional in the field of biomedical sciences.
Olga Alexeeva, a Stanford MBA graduate and former McKinsey consultant, has over 10 years of strategic leadership experience in biopharma and laboratory devices. As Director at Personalis, she organizes efforts for the company-wide product portfolio and is launching NeXT Personal molecular residual disease assay. At Natera, Olga drove the usage and expansion of Signatera MRD in genitourinary cancers by working with cross-functional teams on data generation, KOL relationships, sales training, and fueling pharma collaboration.